ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Inhibition of BCR-ABL tyrosine kinase by Imatinib (IM, formerly STI571, Gleevec®) set new standards in the treatment of chronic myeloid leukemia (CML).